

WHAT IS CLAIMED IS:

- 1 1. An isolated polynucleotide as set forth in SEQ ID NOS: 1-3, 5, 7, 9,
2 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53,
3 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108,
4 110-113, 115-116, 118, or 124 wherein said polypeptide encodes a polypeptide or an
5 immunogenic fragment thereof.
- 1 2. An expression vector comprising a polynucleotide of claim 1 operably
2 linked to an expression control sequence.
- 1 3. A host cell comprising an expression vector according to claim 2.
- 1 4. An immunoconjugate comprising an antibody that specifically binds to
2 a polypeptide or immunogenic fragment thereof encoded by a polynucleotide of claim 1.
- 1 5. The immunoconjugate of claim 4, wherein the antibody is linked to an
2 effector molecule.
- 1 6. The use, in the manufacture of a medicament, of an immunoconjugate
2 according to claim 4 as an active ingredient in a composition for treating cancer.
- 1 7. The method of claim 6, wherein the cancer is multiple myeloma cell.
- 1 8. The method of claim 6, wherein the cancer is chronic lymphocytic
2 leukemia.
- 1 9. An isolated polypeptide comprising an amino acid sequence as set
2 forth in SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54,
3 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121.
- 1 10. An isolated antibody that specifically binds to a polypeptide of claim 9
2 or an immunogenic fragment thereof.
- 1 11. An immunoconjugate comprising an antibody as set forth in claim 10.
- 1 12. The immunoconjugate of claim 11, wherein the antibody is linked to
2 an effector molecule.

1 13. The immunoconjugate of claim 12, wherein the effector molecule is a
2 therapeutic moiety.

1 14. The use, in the manufacture of a medicament, of an immunoconjugate
2 according to claim 11 as an active ingredient in a composition for treating cancer.

1 15. The method of claim 14, wherein the cancer is multiple myeloma.

1 16. The method of claim 14, wherein the cancer is chronic lymphocytic
2 leukemia.